Assessment cycle 2026 Q2

Record of documents ratified in the 2026 Q2 assessment cycle.

Consultation on the draft scoping review of change in lean mass during pharmacologically induced weight reduction. The review is scoping rather than an intervention…

Consultation on the draft standard for freeze–thaw and in-use stability assessment of reconstituted peptide solutions. The draft specifies the cycling regime, the hold…

Consultation on the draft synthesis of incretin receptor agonists for metabolic dysfunction-associated steatohepatitis. The anchor outcome is histological, which raises…

Consultation on the draft monograph for orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist. The draft assesses a compound whose phase 3 programme…

Consultation on the draft monograph for KPV, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…

Consultation on the draft monograph for Lixisenatide, which the assessment committee released for public comment before ratification. The draft grades the compound's…

Consultation on the draft monograph for MOTS-c, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…

Consultation on the draft monograph for Pramlintide, which the assessment committee released for public comment before ratification. The draft grades the compound's…

Consultation on the draft monograph for PT-141 (bremelanotide), which the assessment committee released for public comment before ratification. The draft grades the…

Consultation on the draft monograph for Sermorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's…

Consultation on the draft of CEI-MS-04, which specifies the performance a determination must achieve for content and states what the resulting figure does not establish…

Consultation on the draft of CEI-MS-20, which specifies the performance a determination must achieve for stability and states what the resulting figure does not…

For neuropeptides holding a national marketing registration outside the jurisdictions the Institute routinely reviews, what evidence is retrievable and what can be…

Does the cardiovascular effect of a glucagon-like peptide-1 receptor agonist established in secondary prevention extend to a primary-prevention population?

In the population defined for type 2 diabetes mellitus, what is the effect of Dulaglutide compared with the comparator used in its contributing trials on the anchor…

In the population defined for type 2 diabetes mellitus, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on the anchor…

In the population defined for immune modulation and adjunctive immunotherapy, what is the effect of Thymosin alpha-1 compared with the comparator used in its…

In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with its…

In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Dulaglutide compared with its comparator?

In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its comparator?

In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Lixisenatide compared with its comparator?

In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Semaglutide, oral compared with its…

In the population defined for hypoactive sexual desire and erectile dysfunction, what is the incidence of adverse events leading to discontinuation with PT-141…

In the population defined for obesity and overweight in adults, is the effect of Tirzepatide maintained across the full duration of the contributing trials?

In the population defined for obesity and overweight in adults, is the effect of Survodutide maintained across the full duration of the contributing trials?

Obesity arising from structural hypothalamic injury or a defined genetic syndrome affecting the melanocortin pathway or energy homeostasis.

A pattern of alcohol use characterised by impaired control, salience, and physiological features, meeting recognised diagnostic criteria.

Pharmacological modification of innate or adaptive immune function, assessed by cell counts, functional assays and clinical infection or oncological endpoints.

Oral non-peptide GLP-1 receptor partial agonist. Orforglipron activates the GLP-1 receptor from a non-peptide scaffold, producing the insulinotropic, glucagonostatic and central appetite effects of…

Octapeptide tight-junction regulator (zonulin antagonist). Larazotide antagonises zonulin-mediated tight-junction disassembly, reducing paracellular permeability in intestinal epithelium. The therapeutic…

Synthetic ACTH(4-10) analogue heptapeptide. Semax is reported to increase expression of brain-derived neurotrophic factor and its receptor TrkB in rodent hippocampus, and to modulate…

Endogenous tripeptide thiol antioxidant. Glutathione is the dominant intracellular low-molecular-weight thiol and the cofactor of the glutathione peroxidase and S-transferase systems…

Determination of peptide content and its distinction from chromatographic purity

Freeze–thaw and in-use stability assessment of reconstituted peptide solutions

Peptides, SARMs, injectable oils and raw materials. Long-established synthesis operation.

Research peptides with a worldwide warehouse network. Founded 2017.

Peptides with a global warehouse network. Trades as GGPeps.